ARTICLE | Company News

F-star, F-star Beta deal

November 10, 2014 8:00 AM UTC

F-star's F-star Biotechnology Ltd. subsidiary launched newco F-star Beta and granted it exclusive, worldwide rights to develop and commercialize antibody fragments and bispecific antibodies against certain cancer and immuno-oncology targets. F-star Biotechnology is eligible for milestones and tiered royalties. F-star said specific terms are not disclosed.

F-star Beta's license spans 22 undisclosed oncology and immuno-oncology targets that F-star had previously licensed to F-star Alpha. F-star Beta has early discovery programs against two of the targets and plans to add two to four more by next year. ...